Skip to content
Oncology Research Hub

St Louis, Missouri

Cancer clinical trials in St Louis, MO

287 cancer studies are recruiting participants at sites in St Louis as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

St Louis at a glance

  • 287 studies are recruiting at a site in St Louis.
  • By phase: Phase 1 (55), Phase 1/2 (46), Phase 2 (58), Phase 2/3 (6), Phase 3 (74), Phase 4 (1), No phase (24), Observational (23). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (148), university, hospital or other (105), government (34).
  • By research area: Breast Cancer (86), Lung Cancer (70), Lymphoma (55), Prostate Cancer (40), Pancreatic Cancer (24), Melanoma (12).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in St Louis

Basic details from each study's public record (the 30 most recently updated of 287). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    LeonaBio
    Study site
    Washington University School of Medicine
    Registry record
    NCT05696626 · updated
  2. WashU DIEP Flap Video and Patient Understanding Improvement

    • No phase
    • Ages 18 and older
    • Female participants
    Sponsor
    Washington University School of Medicine
    Study site
    Washington University School of Medicine
    Registry record
    NCT06864754 · updated
  3. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
    Registry record
    NCT03418961 · updated
  4. Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Siteman Cancer Center at Christian Hospital · Siteman Cancer Center-South County · Washington University School of Medicine
    Registry record
    NCT03606967 · updated
  5. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
    Registry record
    NCT05564377 · updated
  6. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
    Registry record
    NCT06058377 · updated
  7. A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pliant Therapeutics, Inc.
    Study site
    Washington University Medicine
    Registry record
    NCT06270706 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in St Louis, MO on ClinicalTrials.gov.

Lung cancer studies recruiting in St Louis

  1. A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Washington University School of Medicine ( Site 3279)
    Registry record
    NCT07513376 · updated
  2. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
    Registry record
    NCT04267848 · updated
  3. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Missouri Baptist Medical Center
    Registry record
    NCT04665739 · updated
  4. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Mercy Hospital Saint Louis · Mercy Hospital South
    Registry record
    NCT06096844 · updated
  5. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Mercy Hospital Saint Louis · Mercy Hospital South
    Registry record
    NCT06498635 · updated
  6. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Washington University School of Medicine
    Registry record
    NCT07100080 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in St Louis, MO on ClinicalTrials.gov.

Prostate cancer studies recruiting in St Louis

  1. High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    VA Office of Research and Development
    Study site
    St. Louis VA Medical Center John Cochran Division, St. Louis, MO
    Registry record
    NCT05011383 · updated
  2. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
    Registry record
    NCT04423211 · updated
  3. Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Washington University School of Medicine-Internal Medicine/Oncology ( Site 0062)
    Registry record
    NCT06136624 · updated
  4. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
    Registry record
    NCT03866382 · updated
  5. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Amgen
    Study site
    Washington University
    Registry record
    NCT04221542 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in St Louis, MO on ClinicalTrials.gov.

Melanoma studies recruiting in St Louis

  1. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Mercy Hospital South · Siteman Cancer Center at Christian Hospital · Siteman Cancer Center-South County
    Registry record
    NCT05136196 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in St Louis, MO on ClinicalTrials.gov.

Lymphoma studies recruiting in St Louis

  1. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study sites
    Siteman Cancer Center at Christian Hospital · Siteman Cancer Center-South County · Washington University School of Medicine
    Registry record
    NCT06724237 · updated
  2. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Mercy Hospital Saint Louis · Mercy Hospital South · Siteman Cancer Center at Christian Hospital
    Registry record
    NCT03739814 · updated
  3. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
    Registry record
    NCT04269902 · updated
  4. Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Siteman Cancer Center-South County · Washington University School of Medicine
    Registry record
    NCT04301076 · updated
  5. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Cardinal Glennon Children's Medical Center · Mercy Hospital Saint Louis · Washington University School of Medicine
    Registry record
    NCT04546399 · updated
  6. Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Mercy Hospital South
    Registry record
    NCT04840602 · updated
  7. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Cardinal Glennon Children's Medical Center · Mercy Hospital Saint Louis · Siteman Cancer Center at Christian Hospital
    Registry record
    NCT05675410 · updated
  8. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Missouri Baptist Medical Center · Siteman Cancer Center at Christian Hospital · Siteman Cancer Center-South County
    Registry record
    NCT06337318 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in St Louis, MO on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in St Louis

  1. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Washington University
    Registry record
    NCT07644559 · updated
  2. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
    Registry record
    NCT04858334 · updated
  3. Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Washington University School of Medicine
    Registry record
    NCT05372614 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in St Louis, MO on ClinicalTrials.gov.

Ask about studies near St Louis

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call